Despite the difficult challenges of operating in a global pandemic, biopharma companies have advanced a field of vaccine candidates for COVID-19 and milestone treatments for Alzheimer’s, heart failure and other conditions.
These therapeutics are likely to achieve blockbuster status by 2025, per Clarivate analysis, and could transform treatment paradigms for the benefit of millions of patients worldwide.
In addition to this year’s Drugs to Watch™, we’ve identified a number of treatments that merit mention for their potential.
These include: CAR T-cell immunotherapies from Bristol Myers Squibb (idecabtagene vicleucel) and Janssen (ciltacabtagene autoleucel); Reata’s anti-inflammatory bardoxolone methyl; Pfizer and Lilly’s NGF inhibitor tanezumab; monoclonal antibodies for treatment of atopic dermatitis from LEO Pharma (tralokinumab) and Galderma’s (nemolizumab); and Pfizer’s PF-06482077 experimental pneumonia vaccine.
Drugs to Watch showcases drugs entering the market with potential to realize $1 billion USD annual sales within five years, based on interviews with therapy experts; Clarivate drug, disease landscape and forecast reports; Cortellis™ sales data; and other industry sources.
“After years of declining R&D productivity, the last five years has seen an increase in approvals of innovative medicines at a rate more than double what it was a decade ago. A number of drivers have aligned to achieve this improvement, including greater insight into the biological roots of diseases, oncology research benefiting from the routine introduction of biomarkers to better target therapies, the emergence of gene and cell therapies and efforts by regulatory agencies to introduce processes to accelerate medicine assessment.”
In the teeth of a global crisis, pharmas and biotechs worked at a furious pace, often collaboratively, to generate a pipeline of effective vaccines, some making it to the public scarcely a year into the pandemic.
This year’s Drugs to Watch also includes a special section on the COVID-19 vaccine landscape, which summarizes the vaccines that were granted emergency use authorizations/conditional approvals as of February 10, 2021.
Dive into additional content and stay up to date on the Drugs to Watch 2021.